Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Antisynthetase syndrome
Rheumatology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending
!
Rapidly progressive antisynthetase lung disease
Increasing oxygen need, tachypnoea or new ground-glass and organising change over days to weeks can progress to respiratory failure even when CK and limb strength are modest.
Action: Admit, support oxygenation, send bacterial, viral and opportunistic microbiology, assess embolic and cardiac causes, and coordinate urgent respiratory-rheumatology high-dose glucocorticoid plus steroid-sparing combination treatment.
Overview
Recognise antisynthetase syndrome when interstitial lung disease, myositis, arthritis and characteristic skin or vascular clues cluster, interpret antibody testing carefully, and treat lung-threatening disease with coordinated early combination immunosuppression.
Antisynthetase syndrome is an autoimmune myositis-spectrum condition defined by an antibody to an aminoacyl-tRNA synthetase plus a compatible phenotype, most importantly ILD, inflammatory myopathy, arthritis, Raynaud phenomenon, fever and mechanic hands. Anti-Jo-1 is the most familiar antibody, but PL-7, PL-12, EJ, OJ and others often present with lung-predominant disease. The full feature set may unfold over years, so a narrow muscle-only assessment misses clinically important cases.
Lung disease determines much of the serious risk. HRCT frequently shows NSIP, organising pneumonia or a mixed pattern, while UIP-like fibrosis occurs in some patients. Rapidly progressive inflammatory ILD may worsen over days to weeks, especially in overlap phenotypes. Respiratory infection is the closest and most dangerous mimic because glucocorticoid can temporarily reduce fever while accelerating pathogen growth. Obtain microbiology and consider bronchoscopy when it changes care without postponing life-saving respiratory support.
Aetiology
01
Antisynthetase autoimmunity
Autoantibodies target aminoacyl-transfer-RNA synthetases, most commonly histidyl-tRNA synthetase Jo-1, within a genetically and environmentally susceptible immune system.
02
Lung and exposure interaction
Smoking, occupational inhalation and respiratory mucosal injury may influence antigen expression and phenotype, although no single exposure is necessary or sufficient.
03
Heterogeneous antibody subtypes
Jo-1, PL-7, PL-12, EJ, OJ and other antisynthetase antibodies associate with differing muscle and lung prominence, severity and relapse patterns.
Pathophysiology
1
Shared lung-muscle autoimmunity
Immune responses to synthetase antigens activate lymphocytes and innate pathways in lung, muscle, synovium and skin, producing a linked but variably expressed syndrome.
2
Inflammatory alveolar injury
Cellular inflammation and organising injury often create NSIP, organising-pneumonia or mixed HRCT patterns that may respond before irreversible fibrosis dominates.
3
Muscle-fibre inflammation
Inflammatory and sometimes necrotising muscle injury causes proximal weakness and enzyme release, but muscle disease may be absent or delayed when ILD dominates.
4
Relapse and fibrotic repair
Recurrent immune activity during taper can cause cumulative lung fibrosis, traction change and pulmonary vascular stress despite improvement in joints or CK.
Clinical features and red flags
Lung-predominant presentation
Cough, exertional breathlessness, crackles, restriction or gas-transfer loss can precede muscle weakness and may be the only initial organ manifestation.
Inflammatory myopathy
Subacute symmetrical proximal and neck weakness, elevated CK, muscle MRI oedema and dysphagia support muscle involvement, although enzymes can be normal.
Mechanic hands
Hyperkeratotic, fissured radial fingers and palms with rough lateral surfaces support antisynthetase disease after occupational and irritant dermatitis are considered.
Inflammatory arthritis
Symmetrical small-joint synovitis or episodic non-erosive polyarthritis may precede lung and muscle disease and can mimic rheumatoid arthritis.
Rapidly progressive ILDRed flag
Increasing oxygen need and bilateral ground-glass or organising change over days to weeks is an emergency despite modest CK or muscle findings.
Bulbar or ventilatory weaknessRed flag
Wet voice, choking, weak cough, orthopnoea or low supine vital capacity identifies aspiration and ventilatory risk beyond parenchymal ILD.
Red flags requiring action
Rapidly worsening dyspnoea, resting hypoxia, falling FVC or diffuse new HRCT change requires same-day assessment for ILD progression and infection.
Dysphagia, weak cough, low supine FVC or hypercapnia suggests bulbar or respiratory muscle involvement in addition to parenchymal lung disease.
Investigations
01Myositis antibody panelFirst step
Why
Identify an antisynthetase specificity and associated risk phenotype within compatible clinical disease.
Interpretation and limitations
Confirm unexpected low-level or multiple line-blot results with laboratory advice; antibody positivity without clinical features is not sufficient for diagnosis.
02HRCT chest
Why
Define ILD pattern, extent, acute inflammatory change and established fibrosis.
Interpretation and limitations
NSIP and organising patterns are common but not specific; compare infection, oedema, aspiration and exposure history and discuss in an ILD multidisciplinary meeting.
03FVC, lung volumes, DLCO and oxygen assessment
Why
Quantify respiratory severity, progression and response using repeatable physiological measures.
Interpretation and limitations
FVC decline supports progression, while DLCO also falls with pulmonary vascular disease, anaemia and emphysema; include exertional desaturation.
04CK, aldolase, AST, ALT, LDH and muscle assessment
Why
Detect muscle injury and establish objective strength and functional baseline.
Interpretation and limitations
Normal enzymes do not exclude lung-predominant syndrome; evaluate weakness with MRI, EMG or biopsy when the mechanism remains uncertain.
Differential diagnosis
01
Infection
Viral pneumonitis, Pneumocystis, bacterial pneumonia, mycobacteria and fungal disease can mimic ILD progression, particularly after glucocorticoid and multidrug immunosuppression.
02
Other connective-tissue ILD
Systemic sclerosis, rheumatoid arthritis, MDA5 dermatomyositis, Sjogren disease and mixed CTD produce overlapping NSIP or organising patterns with different extra-pulmonary clues.
03
Hypersensitivity or drug pneumonitis
Bird, mould and occupational antigens or medicines such as amiodarone and immune therapies can cause inflammatory lung disease with incidental autoantibody results.
04
Idiopathic inflammatory myopathy
Dermatomyositis, immune-mediated necrotising myopathy and inclusion-body myositis may cause weakness without a true antisynthetase antibody or characteristic lung-joint phenotype.
Management
01Diagnostic sequenceConnect lung, muscle, joint and skinFirst stepUnexplained ILD or myositis accompanies mechanic hands, arthritis, Raynaud or fever.+
1Document onset and tempo, occupational and medicine exposures, full skin and joint examination, objective strength, swallowing, cough and respiratory physiology.
2Request HRCT, PFT or DLCO, muscle enzymes and phenotype-led myositis antibodies, confirming discordant serology with the laboratory.
3Discuss lung imaging and pathology in an ILD-myositis multidisciplinary service and use MRI, EMG, biopsy or bronchoscopy for unresolved mechanism.
02Rapid ILD escalationTreat inflammation while excluding infectionEscalationRespiratory symptoms, oxygen or imaging deteriorates over days to weeks.+
1Admit, support oxygenation, send early bacterial, viral, fungal and Pneumocystis testing and assess embolism, aspiration, oedema and respiratory muscle weakness.
Complications
01
Progressive respiratory failure
Rapid inflammatory lung injury or cumulative fibrosis reduces gas transfer, causes oxygen dependence and may lead to ventilation, transplant or death.
02
Pulmonary hypertension
Fibrotic vascular loss, hypoxia and occasional primary vascular disease increase pulmonary pressure and right-heart strain, worsening functional limitation.
03
Bulbar and muscle disability
Proximal, respiratory and swallowing weakness causes falls, aspiration, malnutrition, ineffective cough and impaired work or self-care.
04
Immunosuppression toxicity
Serious and opportunistic infection, cytopenia, renal or liver toxicity, diabetes, osteoporosis, infertility and teratogenicity arise from prolonged combination treatment.
Monitoring and follow-up
During active ILD repeat symptoms, oxygen, FVC and DLCO every one to three months initially and use HRCT when the clinical or physiological trajectory needs explanation.
Measure objective strength, function, CK and swallowing separately; improvement in one compartment must not conceal deterioration in another.
At each respiratory decline obtain early infection testing and review Pneumocystis prophylaxis, vaccination, exposure and immunoglobulins where relevant.
Follow agent-specific FBC, liver, renal, potassium, magnesium, trough, immunoglobulin and hepatitis or TB schedules and document treatment interruptions.
Monitor rehabilitation, oxygen need, weight, aspiration, reflux, pulmonary-hypertension signals, mood, work and caregiver burden.
Review fertility, contraception and pregnancy plans before mycophenolate, methotrexate, cyclophosphamide, rituximab or changes in tacrolimus exposure.
Special situations
The triad is often asynchronous
Lung, arthritis and myositis may appear years apart, so old swollen joints or Raynaud can make current ILD intelligible.
Normal CK does not protect lungs
Non-Jo-1 and lung-predominant disease can be severe while muscle enzymes and limb power remain near normal.
Mechanic hands are contextual
Fissured radial fingers support antisynthetase disease but irritant occupational dermatitis is common and needs the systemic cluster.
One HRCT pattern has many causes
Organising or NSIP change can reflect autoimmune inflammation, infection, aspiration or medicine injury, especially during immunosuppression.
Antibody titre is not a taper target
Lung physiology, oxygenation, imaging behaviour, strength and function determine response more reliably than serial synthetase-antibody level.
Common pitfalls
01
Excluding antisynthetase syndrome because weakness or CK elevation is absent at first ILD presentation.
02
Treating a low-level line-blot antibody as diagnostic without confirming a compatible phenotype or assay reliability.
03
Escalating glucocorticoid for new ground-glass opacity before sampling for opportunistic infection.
04
Following CK while omitting serial FVC, DLCO, oxygen and swallowing assessment.
05
Using prolonged glucocorticoid monotherapy for clinically significant ILD without an early steroid-sparing plan.
06
Allowing pregnancy on mycophenolate or methotrexate because the reproductive discussion focused only on cyclophosphamide.
Practice
Two practice questions
Your practice draft is saved in this browser.
Question 1 of 2
0 correct
RheumatologyOriginal SBA
Lung-first antisynthetase disease
A patient with NSIP-pattern ILD has inflammatory hand arthritis, Raynaud phenomenon and fissured radial fingertips but normal CK and near-normal strength. Which test is most useful next?
Sources and review status6 sources · checked 27 Aug 2026 · clinical review pending+
Sources
Sources and review status
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.
Myositis evaluation includes objective proximal and neck strength, functional tasks, CK and other enzymes, MRI, EMG or biopsy when needed. Normal CK does not exclude lung-predominant antisynthetase syndrome. Arthritis may resemble rheumatoid disease but is often non-erosive; RF and anti-CCP can coexist. Mechanic hands are rough, fissured hyperkeratosis along radial fingers, but occupational dermatitis is common and antibody testing requires the complete systemic context.
Treatment is individualised because randomised syndrome-specific evidence is limited. Significant ILD usually needs glucocorticoid with early mycophenolate, tacrolimus, rituximab, cyclophosphamide or another steroid-sparing agent. Physiotherapy and pulmonary rehabilitation follow stabilisation. Relapse is common during taper, so treatment duration and reduction are based on serial lung physiology and function, not antibody titre. Drug selection explicitly addresses opportunistic infection, vaccination, fertility, pregnancy, renal and liver function and previous cumulative toxicity.
Key points
Suspect antisynthetase syndrome when ILD clusters with inflammatory myopathy, non-erosive arthritis, Raynaud phenomenon, fever or hyperkeratotic fissured mechanic hands.
A patient need not show the full classic triad at presentation; lung disease may precede weakness and CK may remain normal, especially with non-Jo-1 antibodies.
Request an experienced myositis antibody panel when phenotype supports it and confirm surprising line-blot results because low-level isolated reactivity can be false.
At baseline obtain HRCT, spirometry, lung volumes and DLCO, oxygen assessment, CK and muscle function, ECG, echocardiographic risk assessment and swallowing review when indicated.
NSIP, organising pneumonia and mixed NSIP-organising patterns are common; HRCT pattern helps but does not distinguish immune activity from infection without clinical and microbiological synthesis.
For rapidly progressive ILD, admit and treat infection as a parallel possibility while using high-dose glucocorticoid plus an early specialist steroid-sparing agent rather than glucocorticoid alone.
Mycophenolate, tacrolimus, rituximab or cyclophosphamide are selected according to severity, prior treatment, kidney and liver function, infection and reproductive factors; much use is specialist and off-label.
Fever, neutropenia, oral candidiasis or new focal opacity during combined immunosuppression requires urgent opportunistic-infection assessment.
Chest pain, syncope, troponin rise or disproportionate DLCO loss requires evaluation for myocarditis, pulmonary embolism or pulmonary hypertension.
A hot joint with systemic illness needs aspiration and culture; inflammatory arthritis does not protect against septic arthritis.
05Microbiology and bronchoalveolar lavage
Why
Exclude bacterial, viral, Pneumocystis, mycobacterial and fungal infection before or during escalation.
Interpretation and limitations
Select sampling from immune exposure and HRCT; a negative upper-airway sample cannot exclude lower-respiratory opportunistic infection.
06ECG, troponin, NT-proBNP and echocardiography
Why
Assess myocarditis, arrhythmia, ventricular disease and pulmonary-hypertension probability.
Interpretation and limitations
Disproportionate symptoms or DLCO change may require cardiac MRI, CT pulmonary angiography or right-heart catheterisation after specialist review.
07Pre-immunosuppression safety screen
Why
Reduce preventable infection and reproductive harm before multidrug or biologic treatment.
Interpretation and limitations
Check FBC, renal, liver, hepatitis, HIV and TB according to the proposed agent and risk, vaccination history, pregnancy and fertility goals.
2Give intravenous methylprednisolone for a strongly suspected severe inflammatory phenotype and add early specialist tacrolimus, cyclophosphamide, rituximab or other combination according to risk.
3EscalationReview response daily using oxygen, respiratory rate, FVC where feasible, imaging and infection results, escalating critical-care and transplant discussion when decline continues.
03Stable active diseaseUse a steroid-sparing lung planClinically meaningful ILD, myositis or arthritis is active without immediate respiratory failure.+
1Start an appropriate oral glucocorticoid dose and introduce mycophenolate, tacrolimus, azathioprine or another specialist agent early to reduce cumulative exposure.
2Treat arthritis, Raynaud, reflux and aspiration separately and begin graded muscle and pulmonary rehabilitation once inflammation is stabilising.
3Set serial FVC, DLCO, oxygen, strength, CK and swallowing targets and taper only when the threatened organ remains controlled.
04Apparent relapseRecheck infection and mechanismBreathlessness, opacity or weakness returns during treatment or glucocorticoid taper.+
1Review adherence, dose, drug interactions and exact taper and obtain microbiology before assuming immune relapse, particularly during combined immunosuppression.
2Repeat physiology, oxygen, muscle function, CK and focused HRCT and evaluate embolism, pulmonary hypertension, aspiration and fixed fibrosis.
3Intensify or switch immunosuppression only after the dominant active mechanism is defined, and add antifibrotic treatment only for an eligible progressive-fibrosis phenotype.
Key medicines and prescribing safety5 treatments · regimens, roles and cautions+
Rapid suppression of inflammatory muscle, joint and lung disease, usually as one component of combination treatment.
Prednisolone
For active muscle or lung disease, specialists commonly start 0.5–1 mg/kg orally once daily, with lower exposure for milder disease and a documented taper once the steroid-sparing regimen takes effect.
Exclude or treat infection, monitor glucose, pressure, mood, eyes and bone and consider Pneumocystis prophylaxis from total immunosuppressive risk. Never stop prolonged therapy abruptly.
Common steroid-sparing treatment for antisynthetase ILD and associated muscle or skin activity.
Mycophenolate mofetil
Start 500 mg orally twice daily and increase every one to two weeks as tolerated toward 1–1.5 g twice daily under the specialist ILD protocol.
Monitor FBC, liver and renal function, infection and gastrointestinal toxicity. It is teratogenic and requires pregnancy exclusion, effective contraception and planned pre-conception substitution.
Calcineurin-inhibitor option for significant or refractory myositis-associated ILD, often combined with glucocorticoid and another agent.
Tacrolimus
A specialist regimen may start about 0.05–0.075 mg/kg/day orally in two divided doses, then adjust to the service trough target and response rather than a fixed dose.
Monitor trough, creatinine, potassium, magnesium, glucose, pressure, neurotoxicity and CYP3A interactions. It may be used in pregnancy under specialist monitoring, with dose and level changes expected.
B-cell depletion for selected severe or refractory antisynthetase ILD, myositis or arthritis.
Monitor FVC, DLCO, oxygen need, HRCT trajectory, strength, CK and swallowing separately; improved CK does not prove the lungs are controlled.
Provide Pneumocystis prophylaxis when the immunosuppressive combination and local risk threshold indicate it, and screen TB, hepatitis and vaccines before biologic therapy when time allows.
Plan pregnancy during stable disease on compatible treatment; mycophenolate, methotrexate and cyclophosphamide require pre-conception substitution, while tacrolimus and azathioprine may be compatible under specialist guidance.
Rituximab
A common off-label specialist course is 1,000 mg intravenously on days 1 and 15, with retreatment determined by lung or muscle response, immunoglobulins and infection risk.
Specialist off-label use requires hepatitis B and infection screening, vaccination planning, premedication and monitoring for infusion reaction, hypogammaglobulinaemia, late neutropenia and rare PML. Coordinate conception timing with rheumatology.
Prevents Pneumocystis jirovecii pneumonia during sufficiently intense or prolonged glucocorticoid and combination immunosuppression.
Co-trimoxazole Pneumocystis prophylaxis
When prophylaxis is indicated, a common adult regimen is 960 mg orally three times weekly or 480 mg once daily, adjusted for renal function and local protocol.
Check sulfonamide allergy, FBC, renal function and potassium; cytopenia, rash and interaction with methotrexate or warfarin matter. It is not automatic for every patient and reproductive advice is required.